|
|
|
|
|
Conjugated Estrogens
drug data and news
Conjugated Estrogens drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Conjugated Estrogens | ||
| Brand Names/Synonyms | AUSTRIA; BELGIUM; BRAZIL; BULGARIA; CANADA; CHINA; COLOMBIA; COSTA-RICA; Conestoral; DENMARK; DOMINICAN-REPUBLIC; ECUADOR; EL-SALVADOR; ENGLAND; ESTRONE-SULFATE; Estrogens; Estrone Estrone Hydrogen Sulfate; Estrone Hydrogen Sulfate; Estrone Sodium Sulfate; Estrone Sulfate; Estrone Sulfate Sodium; Estrone Sulphate; Evex; FINLAND; FRANCE; GREECE; GUATEMALA; HONDURAS; HONG-KONG; HUNGARY; Hyhorin; INDIA; IRELAND; ITALY; JAPAN; KOREA; MALAYSIA; MEXICO; MIDDLEEAST; Morestin; NETHERLANDS; NEW-ZEALAND; NICARAGUA; Oestrone Sulphate; PANAMA; PERU; PHILIPPINES; PORTUGAL; Par Estro; Premarin; Prempro/Premphase; RUSSIA; SWITZERLAND; Sodium Estrone Sulfate; TAIWAN; THAILAND; TURKEY; URUGUAY; US | ||
| Indication | For the treatment of moderate to severe vasomotor symptoms associated with the menopause, atrophic vaginitis, osteoporosis, hypoestrogenism due to hypogonadism, castration, primary ovarian failure, breast cancer (for palliation only), and Advanced androgen-dependent carcinoma of the prostate (for palliation only) | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Conjugated estrogens, a mixture of the water soluble salts of sulfate esters from estrone, equilin, 17 α-dihydroequilin, and other related steroids, may be derived from pregnant equine urine or yam and soy plants. Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics. They promote growth and development of the vagina, uterus, and fallopian tubes, and enlargement of the breasts. Indirectly, they contribute to the shaping of the skeleton, maintenance of tone and elasticity of urogenital structures, changes in the epiphyses of the long bones that allow for the pubertal growth spurt and its termination, growth of axillary and pubic hair, and pigmentation of the nipples and genitals. Decline of estrogenic activity at the end of the menstrual cycle can bring on menstruation, although the cessation of progesterone secretion is the most important factor in the mature ovulatory cycle. However, in the preovulatory or nonovulatory cycle, estrogen is the primary determinant in the onset of menstruation. Estrogens also affect the release of pituitary gonadotropins. The pharmacologic effects of conjugated estrogens are similar to those of endogenous estrogens. | ||
| Mechanism Of Action | Estrogens enter the cells of responsive tissues (e.g., female organs, breasts, hypothalamus, pituitary) where they interact with a protein receptor, subsequently increasing the rate of synthesis of DNA, RNA, and some proteins. Estrogens decrease the secretion of gonadotropin-releasing hormone by the hypothalamus, reducing the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary. | ||
| Conjugated Estrogens News (When available) |
New Data from Women's Health Initiative Study Show No Increased ... Feb 13, 2006 NEWS RELEASE Feb 14, 2006 (PRN) - Blackboard Inc. Reports Fourth Quarter and Year End 2005 ... Feb 13, 2006 FDA Sends Duramed Warning Letter Over Cenestin Ad Jan 18, 2006 Slurping birth defects Jan 20, 2006 Unopposed Conjugated Equine Estrogens Don't Prevent Peripheral ... Nov 14, 2005 FDA Approves ANGELIQ(R) to Treat Menopausal Moderate to Severe ... Oct 2, 2005 FDA Safety Labeling Changes: Camptosar, Keppra, Prempro/Premphase Sep 21, 2005 Sleep deprivation makes driving dangerous Sep 18, 2005 Does hand washing spread germs? Sep 24, 2005 FDA Safety Labeling Changes: Emtriva, FazaClo, Climara/Climara Pro Sep 14, 2005 FDA Safety Labeling Changes: Activella, Duramorph PF, Nutropin Sep 7, 2005 FDA Safety Labeling Changes: Arixtra and Alora Aug 10, 2005 Kentucky Drug Policy Tweaked; Dialogue to Continue Aug 18, 2005 Latest Stock Information Jul 18, 2005 The Effect of Combined Estrogen and Progesterone Hormone ... Jun 28, 2005 Duramed Pharmaceuticals Selects StayinFront for Integrated CRM ... Jul 1, 2005 Duramed Pharmaceuticals Selects StayinFront for Integrated CRM ... Jul 1, 2005 Hormone therapy market rallies Jun 16, 2005 Effects of Low-Dose Hormone Therapy on Menopausal Symptoms, Bone ... Jun 9, 2005 Effects of Combined Estrogen/Testosterone Therapy on Bone and Body ... May 27, 2005 Hormone therapy market rallies Jun 16, 2005 FDA Safety Labeling Changes: Crestor, Diamox Sequels, Femring Jun 8, 2005 Barr’s Receives Not Approvable Letter for Bijuva(TM) Vaginal ... Apr 26, 2005 Hormone Therapy Remains the Most Effective Therapy for Treating ... Mar 27, 2005 Menopause and Mood Disturbance Feb 14, 2005 HRT May Worsen Urinary Incontinence Feb 22, 2005 | ||
| Dosage Forms | Tablet; Injection; Vaginal Cream; Topical Gel | ||
| Drug_Category | Estrogens; ATC:G03CA57 | ||
| Absorption | well absorbed | ||
| Interactions |
-->Drug Interactions for Conjugated Estrogens: DRUG/LABORATORY TEST INTERACTIONS 1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. 2. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. 3. Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). 4. Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels. 5. Impaired glucose tolerance. 6. Reduced response to metyrapone test. | ||
| Toxicity | nausea and vomiting | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | sodium 13-methyl-17-oxo-3-sulfonatooxy-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene | ||
| Chemical Formula | C18H21NaO5S | ||
| Molecular Weight | 372.412 g/mol | ||
| Smiles String | CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+] | ||
| Melting Point | 173 °C | ||
| Water Solubility | 0.0036 mg/ml | ||
| State | solid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | hepatic | ||
| Half Life | 7.4 hours | ||
| Protein Binding [%] | 90% bound to plasma proteins | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.rxlist.com/cgi/generic/conest.htm http://www.drugs.com/cons/Conjugated_Estrogens.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00396 | ||
| CAS Registry Number | 438-67-5 | ||
| KEGG Compound ID | D00312 | ||
| PubChem ID | SID:7847378 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2239655 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |